What do you think of this strategy in general? Biotech is risky business, but companies typically bottom out after a failed drug trial, assuming that it's a solid companies with innovative capabilities, there's no way to go but up?
I've done some research on MCRB, they are still an innovative company that are researching on promising treatments, this might be a long term hold but I think there's still potential in this company.
Thoughts?
Submitted July 24, 2021 at 10:40AM by scarberia123 https://ift.tt/3kOOBnF
